The H5N1 avian flu is circulating in cows and other mammals. Whether it will make a permanent leap to humans is another ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

At 21-42 days post-vaccination, the geometric mean haemagglutination inhibition titres were 32% higher for H1N1, 55% for H3N2, and 39% for B strains among recipients of the high-dose vaccine than ...

Shares of GSK rose on Thursday after the company announced it had begun shipping its seasonal flu vaccines, Fluarix and ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

including A/H1N1, A/H3N2 and the B/Victoria lineages. Moderna said the vaccine's benefit was consistent across different age groups, people with various risk factors and previous vaccination status ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product ...

(RTTNews) - Biotechnology company Moderna, Inc. (MRNA) announced Monday positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy (rVE) against influenza illness of ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Four drug manufacturers quickly produced a “swine flu” vaccine, which, after trials on 5,000 volunteers, was deemed safe and ready for use.